SenzaGen Q4: Leaving Q4 behind and looking forward to a new year - Redeye

Redeye provides an update following SenzaGen’s Q4 2024 report. The sales during the quarter were disappointing, although we maintain that the long-term investment case remains intact. We have made sales estimate adjustments, which is the main reason for our lowered fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1076806/senzagen-q4-leaving-q4-behind-and-looking-forward-to-a-new-year?utm_source=finwire&utm_medium=RSS